Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Used Invokana Review To Reflect On Diabetes CV Risk Policy

Executive Summary

Agency officials viewed the review of canagliflozin – the first program started after the 2008 outcomes trial requirement – as a chance to look at lessons learned since the policy went into effect.

You may also be interested in...



Will CV Verdicts For Onglyza, Nesina Cause FDA To Change Its Tune On Antidiabetic Safety?

Large outcomes studies showed neither cardiovascular harm nor benefit with BMS/AstraZeneca’s saxagliptin or Takeda’s alogliptin, prompting some commenters to question whether FDA’s blanket approach to CV safety for all antidiabetic agents needs adjustment.

Avandia Review Endorsement Aided By Good Data, Cultural Shift On Safety

Flawed clinical trial overcomes meta-analysis safety signal as mortality data from the re-adjudicated RECORD trial persuades the rosiglitazone advisory committee that the product’s risk management program can be relaxed.

Avandia Panel Wants Another Trial: Pipe Dream Or Post-market Benchmark?

Designed with complex, multi-variate statistics, an observational trial could determine the CV risk of rosiglitazone compared to other diabetes drugs, an advisory committee member suggests during the latest assessment of Avandia.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS078529

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel